Exosome technology:A novel and effective drug delivery system in the field of cancer therapy  

作　　者：Jia-Xin Geng Yao-Fan Lu Jing-Nan Zhou Biao Huang Yuan Qin 

机构地区：[1]College of Life Sciences and Medicine,Zhejiang Sci-Tech University,Hangzhou 310018,Zhejiang Province,China [2]Zhejiang Cancer Hospital,Hangzhou 310018,Zhejiang Province,China

出　　处：《World Journal of Gastrointestinal Oncology》2025年第3期464-469,共6页世界胃肠肿瘤学杂志(英文)

基　　金：Natural Science Foundation of Zhejiang Province,No.LQ23H050005;Zhejiang Medical and Health Science and Technology Project,No.2023KY615;Scientific Research Project of Zhejiang Provincial Education Department,No.Y202250731 and No.Y202353130;the China Students’Innovation and Entrepreneurship Training Program,No.202310338044;China Postdoctoral Science Foundation,No.2022M721720.

摘　　要：In this article,we revisit an article,which specifically focuses on the utilization of exosomes derived from human bone marrow mesenchymal stem cells(MSCs)for targeted delivery of gemcitabine in pancreatic cancer treatment.The experimental results demonstrated that the exosome-based drug delivery system derived from MSCs significantly augmented apoptosis in pancreatic cancer cells.The biocompatibility,targeting specificity,and low immunogenicity of exosomes render them as optimal carriers for drug delivery,enabling precise administration of therapeutics to diseased tissues while mitigating adverse effects,thereby achieving targeted treatment of cancer cells and significantly enhancing anti-tumor efficacy.However,the clinical application of exosome drug delivery platforms in oncology still presents challenges,necessitating further optimization to ensure their stability and efficacy.This study focuses on elucidating the advantages of exosomes as a drug delivery platform,exploring the utilization of MSC-derived exosomes in oncology therapy,and discussing their potential and future directions in cancer treatment.

关 键 词：EXOSOMES Drug delivery Mesenchymal stem cells Tumor therapy GEMCITABINE 

分 类 号：R735.9[医药卫生—肿瘤]